Influence of the cream with filaggrin activity modulator for dry and sensitive skin in children with mild to moderate severity atopic dermatitis on objective indicators of skin barrier function and disease severity indices
- Authors: Zaslavsky D.V.1, Barinova A.N.2,3, Plavinskij S.L.2, Zelyanina M.I.4, Zakharova I.N.5, Berezhnaya I.V.5, Shartanova N.V.6, Sidorovich O.I.6
-
Affiliations:
- Saint-Petersburg State Pediatric Medical University
- North-Western State Medical University named after I.I. Mechnikov
- City Hospital № 26
- The Pierre Wolkenstein French Dermatological Clinic
- Russian Medical Academy of Continuous Professional Education
- National Research Center - Institute of Immunology
- Issue: Vol 26, No 1 (2023)
- Pages: 25-39
- Section: DERMATOLOGY
- URL: https://rjsvd.com/1560-9588/article/view/122220
- DOI: https://doi.org/10.17816/dv122220
- ID: 122220
Cite item
Abstract
BACKGROUND: Atopic dermatitis is a chronic, relapsing and severely itchy dermatitis that usually occurs in childhood and has a characteristic age-related distribution. Atopic dermatitis is relatively frequent, affecting 10–20% of children in developed countries. Atopic dermatitis in children associated with poor school performance, low self-esteem and family problems. Recent studies show importance in atopic dermatitis pathogenesis of protein filaggrin and modulation of its activity may be a promising direction in the pathogenic therapy of atopic dermatitis.
AIM: to study the effect of a cream for dry, sensitive and atopic skin with a modulator of filaggrin activity on the course of mild and moderate atopic dermatitis.
MATERIAL AND METHODS: An open, prospective, multicentre, non-comparative, single-group clinical trial was organized to test the effectiveness of a cream with a filaggrin activity modulator. The study was on outpatients in the participated centers and included 5 visits with a screening visit 1, and 5th visit ― therapy completion. Cream was used for 12 weeks. In total, the study involved 60 children aged 3 to 18 years with diagnoses of atopic dermatitis of mild and moderate severity. The severity of atopic dermatitis was measured with the SCORAD, EASI, IGA scales, also measured was skin pH and transepidermal water loss (TEWL), as well as the severity of xerosis according to visual analogue scale.
RESULTS: The severity of atopic dermatitis in children whose therapy regimens included Admera cream decreased by 19.6 points according to the SCORAD index, including in children who did not receive mometasone furoate in the therapy schemes, the SCORAD index decreased statistically significantly compared to the baseline data (p <0.001). The overall decline in the EASI index ― by 3.0 points, the IGA global assessment index ― by 2.0 points, the severity of xerosis decreased by 3 points (in all cases, p <0.001). Transepidermal water loss decreased (by 4.5 g/m2 per hour, p <0.001); Skin pH did not change (difference 0.02, p=0.34). The smell was rated as "excellent" by 86.7% (95% CI 75.4–94.1), the consistency ― by 83.3% (95% CI 71.5–91.7) of the respondents, and overall satisfaction was noted by ― 88.3% (95% CI 77.4–95.2) of the respondents.
CONCLUSION: Сream for dry and sensitive skin with a modulator of filaggrin activity during the study showed good efficacy and tolerability and can be used in atopic dermatitis treatment regimens as a basic care product, both during exacerbation and remission.
Full Text

About the authors
Denis V. Zaslavsky
Saint-Petersburg State Pediatric Medical University
Author for correspondence.
Email: venerology@gmail.com
ORCID iD: 0000-0001-5936-6232
SPIN-code: 5832-9510
MD, Dr. Sci. (Med.), Professor
Russian Federation, 2 Litovskay street, 194100 Saint-PeterburgAnna N. Barinova
North-Western State Medical University named after I.I. Mechnikov; City Hospital № 26
Email: anna_n_barinova@mail.ru
ORCID iD: 0000-0002-8180-9340
SPIN-code: 2010-4354
MD, Dr. Sci. (Med.), Professor
Russian Federation, Saint Petersburg; Saint PetersburgSviatoslav L. Plavinskij
North-Western State Medical University named after I.I. Mechnikov
Email: s.plavinskij@szgmu.ru
ORCID iD: 0000-0001-9159-6177
SPIN-code: 5660-4661
MD, Dr. Sci. (Med.), Professor
Russian Federation, Saint PetersburgMaria I. Zelyanina
The Pierre Wolkenstein French Dermatological Clinic
Email: m.zelianina@rambler.ru
ORCID iD: 0000-0002-0172-9763
SPIN-code: 3201-9685
MD
Russian Federation, Saint PetersburgIrina N. Zakharova
Russian Medical Academy of Continuous Professional Education
Email: zakharova-rmapo@yandex.ru
ORCID iD: 0000-0003-4200-4598
SPIN-code: 4357-3897
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowIrina V. Berezhnaya
Russian Medical Academy of Continuous Professional Education
Email: berezhnaya-irina26@yandex.ru
ORCID iD: 0000-0002-2847-6268
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, MoscowNatalia V. Shartanova
National Research Center - Institute of Immunology
Email: nshartanova@yandex.ru
ORCID iD: 0000-0002-1197-9002
SPIN-code: 6483-8901
MD, Dr. Sci. (Med.)
Russian Federation, MoscowOlga I. Sidorovich
National Research Center - Institute of Immunology
Email: instimmun@yandex.ru
ORCID iD: 0000-0003-1000-0664
SPIN-code: 9757-8172
MD, Cand. Sci. (Med.), Senior Research Associate
Russian Federation, MoscowReferences
- Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status. Sci Rep. 2020;10(1):2721. doi: 10.1038/s41598-020-59627-7
- Cepelak I, Dodig S, Pavic I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501. doi: 10.11613/BM.2019.020501
- Hoober JK, Eggink LL. The discovery and function of filaggrin. Int J Mol Sci. 2022;23(3):1455. doi: 10.3390/ijms23031455
- Marenholz I, Esparza-Gordillo J, Ruschendorf F, et al. Meta-analysis identifies seven susceptibility loci involved in the atopic march. Nat Commun. 2015;(6):8804. doi: 10.1038/ncomms9804
- Dvornyk V, Ponomarenko I, Belyaeva T, et al. Filaggrin gene polymorphisms are associated with atopic dermatitis in women but not in men in the Caucasian population of Central Russia. PLoS One. 2021;16(12):e0261026. doi: 10.1371/journal.pone.0261026
- Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann Nutr Metab. 2015;66 (Suppl 1):8–16. doi: 10.1159/000370220
- Zaslavsky DV, Barinova AN. Skin microbiome in atopic dermatitis and features of various basic skin care products. Medical council. 2018;(2):170–176. (In Russ). doi: 10.21518/2079-701X-2018-2-170-176
- Clausen ML, Agner T, Lilje B, et al. Association of disease severity with skin microbiome and filaggrin gene mutations in adult atopic dermatitis. JAMA Dermatol. 2018;154(3):293–300. doi: 10.1001/jamadermatol.2017.5440
- O’Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2008;122(4):689–693. doi: 10.1016/j.jaci.2008.08.002
- Strathie PS, Weston S, Loh R. Atopic dermatitis in children. Aust Fam Physician. 2016;45(5):293–296.
- LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol. 2019;36(1):36–65. doi: 10.1111/pde.13678
- Zaslavsky DV, Barinova AN. A new strategy of basic moisturizing therapy for atopic dermatitis — “emolents plus”. Dermatovenerology. Cosmetology. 2019;5(1):69–79. (In Russ).
- HanifIn JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl). 1980;(92):44–47. doi: 10.2340/00015555924447
- Zaslavsky DV, Sobolev AV, Skrek SI, et al. Normalization of the epidermal barrier as a method of pathogenetic therapy of atopic dermatitis in children. Vestnik Dermatologii i venerologii. 2021;97(5):52–65. (In Russ). doi: 10.25208/vdv1255
- Atopic dermatitis. Clinical recommendations. Moscow: The Russian Society of Dermatovenerologists and Cosmetologists, The Russian Association of Allergologists and Clinical Immunologists, The Union of Pediatricians of Russia; 2020. 81 р. (In Russ).
- Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol. 2011;(41):149–155. doi: 10.1159/000323308
- Hanifin JM, Baghoomian W, Grinich E, et al. The eczema area and severity index--A practical guide. Dermatitis. 2022;33(3):187–192. doi: 10.1097/DER.0000000000000895
Supplementary files
